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This advisory is issued by the Board of Registration in Medicine (BORiM), Division of Quality 
and Patient Safety (QPSD). The goal of this advisory is to support health care facilities, 
ambulatory clinics and private physician practices in the review and development of their 
approaches to opioid prescribing practices. While some references are provided, this advisory 
does not include a comprehensive review of the literature. This document is intended to 
encourage judicious and balanced opioid prescribing practice. 
Publication of this advisory does not constitute an endorsement by the BORiM of any studies or 
practices described in the advisory and none should be inferred. 
I. Overview 
Substance misuse is a major public health challenge. Nationally, and in Massachusetts, 
individuals, communities, and health care systems are struggling to cope with substance use 
disorders. Opioid use disorder (OUD) is a substance use disorder that has recently received 
significant attention because the rates of OUD, opioid misuse, and overdose deaths related to 
opioids have reached epidemic levels; in 2017, OUD was declared a public health emergency. 
According to the Centers for Disease Control and Prevention (CDC), more than 90 Americans 
die each day from opioid, including illicit and prescription drugs, overdose. Massachusetts has 
been particularly affected by OUD and overdose, with opioid overdose rates 30% higher than the 
national average.
1
 Additionally, the prevalence of overdose rates in Massachusetts was higher in 
rural counties than in urban counties.
2
 
 
While there was an overall 4% decrease in the number 
of opioid-related overdose deaths in 2017 compared 
with 2016, fentanyl-related deaths are increasing.
3
 The 
surge in overdoses in Massachusetts has been primarily 
attributed to the introduction of fentanyl into the heroin 
market. Fentanyl is a synthetic opioid analgesic 
designed to be similar to morphine but is 50 to 100 times 
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Massachusetts is Working to 
Prevent Opioid Overdose 
 Naloxone is now covered by 
MassHealth (Medicaid) plans. 
 State policy now includes a Good 
Samaritan law to protect civilians for 
administering naloxone to a person 
during an overdose event. 
2 
more potent. In 2018, among the 962 opioid-related overdose deaths where a toxicology screen 
was available, 863 of them (or 90%) had a positive screen result for fentanyl.
4
  
 
In 2015 (latest data available), with respect to age, the OUD prevalence was highest among 
individuals 26 to 44 years old and 45 years old or older (6.87% and 4.66%, respectively).
5
 The 
OUD prevalence in Massachusetts among people ages 11 years or older was 2.72% in 2011 and 
2.87% in 2012. Between 2013 and 2015, the prevalence increased from 3.87% to 4.60%.
6
  
 
II. What are the Best Practices for Prescribing Opioids for Chronic 
and Acute Pain?  
Overarching Considerations  
Two guidelines should be considered when understanding what the best practices are for 
prescribing opioids for chronic and acute pain. The first document is the Massachusetts Medical 
Society Opioid Therapy and Physician 
Communication Guidelines published in August 
2015. The second set of recommendations is 
from the CDC, which published the CDC 
Guideline for Prescribing Opioids for Chronic 
Pain in a March 2016 Morbidity and Mortality 
Weekly Report, to address prescribing 
recommendations in the United States (U.S.).  
 
The Massachusetts guidelines consist of 11 
elements for acute care. First and foremost, the 
guidelines recommend that physicians be familiar 
with and follow the requirements of the law and 
regulations on the use of the prescription 
monitoring program prior to initiating opioid 
treatment. Overall, the Massachusetts guidelines 
are broader and less specific than the CDC 
recommendations. However, both 
recommendations cover areas of concern, such as 
screening for histories of mental health challenges and/or previous substance use disorders, along 
with the starting dosage being the minimum necessary (Massachusetts) or lowest dose necessary 
(CDC).  
 
Note: All prescribes in MA must complete three credit hours of Continuing Professional 
Development (CPD) in opioid and pain management within each two year licensing period. 
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The CDC identifies Specific Dosage 
Considerations 
 
 Starting Dosage: When opioids are started, 
clinicians should prescribe the lowest effective 
dosage. 
 Dosage Changes: Clinicians should use caution 
when prescribing opioids at any dosage, should 
carefully reassess evidence of individual benefits 
and risks when increasing dosage to ≥50 morphine 
milligram equivalents (MME)/day, and should 
avoid increasing dosage to ≥90 MME/day or 
carefully justify a decision to titrate dosage to ≥90 
MME/day. 
 Acute Pain Dosage: When opioids are used for 
acute pain, clinicians should prescribe no greater 
quantity than needed for the expected duration of 
pain severe enough to require opioids; 3 days or 
less will often be sufficient; more than 7 days will 
rarely be needed. 
 
3 
 
The CDC guidelines identify high-risk prescribing practices that have contributed to the 
overdose epidemic. These include high-dose prescribing, overlapping opioid and benzodiazepine 
prescriptions, and extended-release/long-acting (ER/LA) opioids for acute pain. The guidelines 
also address opioid pain medication in several populations, such as older adults and pregnant 
women, and populations with conditions with special risks, such as history of a substance use 
disorder. The guidelines do not address the use of opioid pain medication for children or 
adolescents under 18 years.  
 
The Massachusetts guidelines recommend a duration of a 90-day treatment threshold for chronic 
pain.
7
 After a 90-day threshold has occurred for an individual with chronic pain, the 
Massachusetts guidelines suggest 16 elements, which include: re-evaluating the patient’s history, 
completing an objective pain assessment, screening for substance use disorder, considering the 
use of urine drug testing, developing a treatment plan with functional goals that is reassessed 
every 60-90 days, informing the client about risks and benefits of continued opioid therapy, 
developing treatment agreements, and others.
8
  
 
Above a 90-day threshold, the Massachusetts guidelines recommend a risk assessment of 
substance use disorder using a tool recommended by the Massachusetts Medical Society; 
however, the CDC guidelines suggest that single screening questions can be used to screen 
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Key Considerations from Massachusetts Guidelines 
 
 Patients should also be screened or assessed for pregnancy, personal or family histories of substance use disorder, 
mental health status, or relevant behavioral issues. 
 Physicians prescribing opioids should inform their patients about the cognitive and performance effects of these 
prescriptions and warn them about the dangers to themselves and others in operating machinery, driving, and related 
activities while under treatment. 
 Patients with complex pain conditions, serious comorbidities and mental illness, or a history or evidence of 
substance use disorder should be considered for consultation from a colleague or specialist referral. 
 When clinically indicated, opioids should be initiated as a short-term trial to assess the effects and safety of opioid 
treatment on pain intensity, function, and quality of life. In most instances, the trial should begin with a short-acting 
opioid medication. 
 The starting dosage should be the minimum dosage necessary to achieve the desired level of pain control and to 
avoid excessive side effects. 
 Duration should be short term with possible partial-fill prescriptions or short-term, low-dosage sequential 
prescription approaches considered. 
 Physicians should be aware of published dosing guidelines for pediatric patients, and consider body weight and age 
as a factor in treating pediatric patients. 
 Concurrent prescriptions should be reviewed, including paying close attention to benzodiazepines and other 
medications that may increase the risks of harm with opioid use. 
 Physicians must maintain records and engage in patient assessments consistent with prescribing guidelines of the 
Board of Registration in Medicine (BORiM), and are available on their website. 
 Patients should be counseled to store the medications securely, never share with others, and properly dispose of 
unused and expired prescriptions. 
 Note: All prescribes in MA must complete three credit hours of Continuing Professional Development (CPD) in 
opioid and pain management within each two year licensing period. 
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patients for substance use disorders, including opioid use disorder. Massachusetts guidelines 
should take precedence. 
 
Considerations for Select Medical Specialties  
There are unique considerations for prescribing opioids 
by different areas of medical specialty. Several of these 
considerations are highlighted below. 
 
Palliative Care 
Palliative care represents a unique situation in terms of 
pain management. While the CDC guidelines provide 
recommendations for the prescribing of opioid pain 
medication and strongly advise against opioids for the 
routine management of chronic pain, patients receiving 
active cancer treatment have ongoing pain after 
chemotherapy and/or during or after radiation, are 
exceptions, as are palliative care and end-of-life care 
patients. Pain care becomes palliative care when three 
criteria are met: 1) the underlying disease has no cure; 
2) there is a likelihood that the disease may shorten 
lifespan; and 3) symptomatic treatment has a high 
probability of improving the quality of life.
9
 Therefore, 
recommendations regarding opioid pain management in 
palliative care may be taken into consideration for both cancer and non-cancer patients. The 
CDC guidelines are advisory, not mandatory, but are likely to influence physicians’ prescribing 
patterns. Some hospice and palliative care providers are concerned that, while cancer, palliative, 
and end-of-life patients are exempt, the CDC guidelines could have a negative impact on this 
patient population.
10
 For many years, hospice and palliative care providers have provided pain 
management, including safely prescribed opioids, even at high doses, when clinically indicated. 
Opioids play a key role in alleviating pain and suffering for those with advanced illness and at 
the end of life.
11
 The Massachusetts guidelines specifically state that they do not apply to patients 
with cancer or patients in hospice or palliative care. Findings from a study on attitudes of health 
care professionals to opioid prescribing in end-of-life care revealed that significant barriers exist 
to the appropriate use of opioids in end-of-life care.
12
 Particular barriers exist for providers 
working in primary care and include concerns about giving high doses and having insufficient 
training in opioid use. Furthermore, patients and their families often have concerns about 
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INNOVATIVE PRACTICE  
Auricular Acupuncture 
  
 Researchers examined the feasibility, 
credibility, and effectiveness of 
auricular acupuncture to reduce pain 
severity. 
 45 participants; 8-day study period 
 Standard auricular acupuncture 
protocol-penetrating semi-permanent 
acupuncture needles in place for up to 
4 days.  
 RESULTS: Auricular acupuncture 
reduced pain and insomnia, compared 
to usual care.  
(Garner, Hopkinson, Ketz, Landis, Trego 
(2018). Auricular Acupuncture for 
Chronic Pain and Insomnia: A 
Randomized Clinical Trial. Med 
Acupuncture, 30 (5), 262-272) 
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initiating opioids, and often associate opioids with addiction or imminent death.
13
 However, 
generally patients have been found to be comfortable with many aspects of chronic pain 
management, such as discussing/recommending non-opioid pharmacologic and non-
pharmacologic therapies. Palliative care providers report low confidence managing opioid 
misuse behaviors, and many do not have systems in place to utilize urine drug testing, to taper 
opioids, or to treat opioid addiction.
14
 Good communication between provider and patients or 
families is essential in these circumstances. 
 
Recently, attention has been given to emerging options to opioids for pain treatment. Studies 
have shown that methadone may be effective as a first-line drug in the management of cancer 
pain, providing similar analgesia and adverse effect profiles to those produced by other opioids. 
In particular, methadone doses seem to remain more stable in time, with slow escalation indexes. 
Methadone has been used at doses approximately equivalent to oral morphine equivalents of 
60 mg/day, as it commonly occurs in patients who start Step 3 of the analgesic ladder.”15  
 
In addition, in treatment of non-cancer pain, compared with placebos, opioids were associated 
with small improvements in pain, physical functioning, and sleep quality. Compared with 
placebos, opioids were associated with increased vomiting, drowsiness, constipation, dizziness, 
nausea, dry mouth, and pruritus.
16
 In a meta-analysis of patients with chronic non-cancer pain, 
evidence from high-quality studies showed that opioid use was associated with statistically 
significant but small improvements in pain and physical functioning, and increased risk of 
vomiting compared with placebo. Comparisons of opioids with non-opioid alternatives suggested 
that the benefit for pain and functioning might be similar, although the evidence was from 
studies of only low to moderate quality.
17
  
 
Surgical  
Surgery is a common setting in which opioid-naive patients are first exposed to opioids, with one 
study demonstrating that 1 in 16 patients become long-term users after surgery.
18
 
Overprescribing opioids after surgery is common, and the lack of multidisciplinary procedure-
specific guidelines contributes to the wide variation in opioid prescribing practices.
19
 The CDC 
guidelines described above have only one paragraph addressing acute pain recommendations. 
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The guideline recommends not exceeding a 7-day supply but do not specify the morphine 
milligram equivalents (MME). This is problematic because a single day’s supply spans the range 
of up to 90 morphine MME per day, depending on how the prescription is written.
20
 
Furthermore, using a day’s supply fails to account for important risks that accompany higher 
opioid doses, such as the risk of overdose that doubles at or above 50 MME/day compared with 
prescriptions of less than 20 MME/day.
21
 The Massachusetts guidelines state that for acute care, 
the starting dosage should be the minimum dosage necessary, and the duration should be short 
term with possible partial-fill prescriptions. Massachusetts state guidelines should take 
precedence. 
 
Surgical procedures vary considerably in pain intensity, though many payers and other decision-
making bodies have tried to apply a one-size-fits-all approach. Currently, best practices for 
opioid prescribing after surgery exist mainly in the experience and wisdom of providers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consistent among studies related to prescribing opioids after surgical procedures is that there is a 
lack of clear guidelines, leaving many surgeons on their own in determining the appropriate 
quantity and strength of opioids needed to address their patients’ pain. Recently, in August 2018, 
a panel of Johns Hopkins University experts announced the first set of 20 operation-specific 
opioid prescribing guidelines (https://www.mdmag.com/medical-news/johns-hopkins-releases-opioid-
prescribing-recommendations-for-surgeries).
22
 Prior to that, the American College of Surgeons had 
provided practical guidelines based on a consensus of both physicians and patients. 
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Massachusetts Health and Hospital Association Guidelines 
1. Guidelines for Medication for Addiction Treatment for Opioid Use Disorder within the 
Emergency Department: 
http://patientcarelink.org/wp-content/uploads/2019/01/18-01-04MATguidelinesNEWFINAL.pdf 
2. Guidelines for Opioid Management within a Hospital Setting: 
http://patientcarelink.org/wp-
content/uploads/2017/06/SUDPTTFGuidelinesforPrescriptionOpioidManagementwithinHospitals
.pdf  
3. Guidelines for ED Opioid Management:   
http://patientcarelink.org/wp-content/uploads/2017/06/SUDPTTF-ED-GuidanceDocument.pdf 
4. Guidelines for Preventing Opioid Misuse in Hospitals:  
http://patientcarelink.org/wp-content/uploads/2018/07/18-07-24-Inpatient-Opioid-Misuse-
Prevention-GuidelinesFINAL.docx 
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Emergency Medicine 
While concerns over opioid 
prescription misuse are shared by 
all medical providers, emergency 
medicine practitioners are at the 
nexus of the growing use of 
prescription pain medication and 
the devastating consequences of 
opioids, with nearly 43% of 
emergency department visits being 
related to pain.
23
 It is important to 
note that while Emergency 
Department (ED) opioid 
prescribing has increased, many of 
the misuse cases are with 
individuals using the long-acting or 
extended-release formulations to 
treat chronic pain.
24
 For patients 
with chronic pain, it is critical to 
assess the adequacy of pain relief 
and the adjunct agent being used 
for treatment. If the pain is not 
relieved, the patient may continue 
to escalate the dosing. 
 
The long-lasting or extended-
release agents are rarely prescribed 
in the ED, likely because the 
majority of painful conditions seen 
in the ED are acute in nature.
25
 
Although relieving pain and 
reducing suffering are primary 
emergency physician 
responsibilities, there is a 
concurrent duty to limit the 
personal and societal harm that can 
result from prescription drug 
misuse. Several state efforts to 
address potential misuse have 
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Substance Use Disorder Evaluations (SUDE) 
Massachusetts Requirements 
 
Massachusetts State law requires Emergency Departments to: 
1. Complete a SUDE for patients reasonably believed to be 
experiencing an opioid-related overdose or who were administered 
naloxone prior to arriving at the ED or Satellite Emergency Facility 
(SEF), and record findings of the SUDE in the patients electronic 
medical record (EMR). 
2. Maintain capacity to provide appropriate, evidence based 
interventions, including initiating or providing Medication Assisted 
Treatment (MAT) for OUD.   
3. Offer to initiative or provide MAT for OUD to all patients 
following an overdose and prior to discharge. 
4. Prior to discharge, directly connect patients who receive MAT to an 
appropriate provider or treatment site to continue MAT or other 
community based program appropriate to the patient’s needs.  
 
Guidance on conducting a SUDE as part of a hospital’s clinical 
practices once a patient has been stabilized and medically cleared, in 
accordance with Section 51 ½ of Chapter 111 of the MA General Laws.  
 
1. The treating physician or clinician must order a SUDE for the 
following patients based on the patient’s clinical presentation 
within a hospital (including any satellite emergency facility). 
2. The SUDE should occur regardless of treatment and follow up care 
location 
3. Treating physician or clinician should monitor timing of SUDE.  
4. Licensed Mental Health Professional or ESP conducting a SUDE 
must: 
a. Provide evaluation that includes at a minimum the 
following criteria: history of patient’s substance use, 
family history of substance use, assessment of the 
patient’s psychological treatment history, psychological 
status, and risk status for HIV, Hepatitis C, and 
Tuberculosis. 
b. Diagnose status and nature of the patient’s substance use 
disorder. 
c. Deliver findings of SUDE to patient verbally and in 
writing, and document in the hospital record. 
5. Follow mandatory follow up steps with patients receiving a SUDE. 
 
Additional information available from source where above content was 
directly extracted:  
Guidelines for Substance Use Disorder Evaluations: 
http://patientcarelink.org/improving-patient-care/substance-use-
disorder-prevention-treatment-2/ 
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included the development of statewide opioid prescribing guidelines for emergency 
physicians/departments. In addition to emergency physicians attending trainings to qualify for a 
waiver, examples include Pennsylvania EDs limiting prescriptions for opioids by starting with 
lowest effective dose or addressing pain with non-opioids, Washington EDs utilizing information 
exchange programs, and New York EDs providing patient education information.   
 
One option for ED physicians is to complete the eight-hour training to qualify for a waiver to 
prescribe and dispense buprenorphine. Recommendation 12 in the CDC guidelines, described in 
more detail above, suggests that clinicians refer patients with OUD to evidence-based treatment, 
usually medication assisted treatment (MAT) with buprenorphine or methadone in combination 
with behavioral therapies.
26
 
 
One study indicates that ED-initiated buprenorphine is cost-saving, compared to a brief 
intervention or referral.
27
A separate study found that opioid-dependent patients who received 
ED-initiated buprenorphine with continuation in primary care were more likely to be engaged in 
treatment and reported less use of illicit opioids at the time of follow-up assessments at two 
months.
28
 
III. What Can Physicians Do to Identify and Triage Opioid Use 
Disorders?  
Several tools have been developed to assist health care providers in identifying and triaging 
opioid use disorder. A sample of tools and recommended guidelines is provided below.  
A. Screening Methods and Instruments  
The Massachusetts guidelines indicate that patients should be screened for personal or family 
histories of substance use disorder. The Massachusetts Health and Hospital Association (MHA) 
developed a document to provide an overview of commonly used screening tools for substance 
use disorders. Several links to these screening tools, along with the link to the MHA resource 
document, are listed in the box on page 9. In addition, the CDC reports that asking the single 
question,  “How many times in the past year have you used an illegal drug or used a prescription 
medication for nonmedical reasons?” was found in a primary care setting to be 100% sensitive 
and 73.5% specific for detecting a drug use disorder compared to a standardized diagnostic 
interview.
29
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Screening tools can provide a systematic and timely method for routine assessment of patients in 
a range of medical treatment settings. However, these tools should not be relied on too much. 
Specifically, the CDC notes “the clinical evidence review found that currently available risk-
stratification tools (e.g., Opioid Risk Tool, Screener and Opioid Assessment for Patients with 
Pain Version 1, SOAPP-R, and Brief Risk Interview) show insufficient accuracy for 
classification of patients as at low 
or high risk for abuse or misuse.”30 
It is important to examine the 
limitations of each tool and 
combine the results from the tools 
with other sources of information 
for assessing risk, such as 
accessing the state prescription 
drug monitoring program (PDMP) 
or urine testing. 
 
 
B. Brief Intervention in 
Primary Care for Opioid 
Misuse or Opioid Use 
Disorder 
The screening, brief intervention, 
and referral to treatment (SBIRT) 
is a public-health approach to 
substance use that focuses on 
using the medical setting as a 
unique opportunity to provide a 
brief motivational discussion 
around risky substance use.
31
 
Following the SBIRT model, if an 
individual’s screening score is in a 
moderate- to high-risk category, a provider should implement a brief intervention, taking only 5–
10 minutes. A brief intervention is a patient-centered intervention that uses motivational 
interviewing to effect behavioral change in a short time period. The purpose of motivational 
interviewing is not to “cure the patient’’ but to instill in him or her a desire to change by pointing 
out discrepancies between current behavior and future goals.
32  
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Commonly Used Screening Tools for Risky Opioid 
Use 
  
DRUGS/MEDICATIONS  
 NIDA-1 (National Institute on Drug Abuse: 1 Question) 
 DAST-10 (Drug Abuse Screening Test; 10 questions) 
 SAMHSA Opioid Overdose Toolkit: (List of 6 criteria) 
 The 5Ps Prenatal Substance Abuse Screen for Alcohol 
and Drugs  
 
POLYSUBSTANCE  
 CRAFFT (Pediatric; 5-6 questions) 
 ASSIST (Alcohol Smoking and Substance Involvement 
Screening Test; 7 questions) 
 
LONG-TERM PAIN THERAPY  
 ORT (Opioid Risk Tool; 5 questions)  
 SOAPP (Screener and Opioid Assessment for Patients 
with Pain; 5-24 questions)  
 
Additional Details on Tools: 
– http://www.integration.samhsa.gov/clinical-
practice/screening-tools 
– https://store.samhsa.gov/system/files/sma18-4742.pdf 
– http://patientcarelink.org/wp-
content/uploads/2017/07/ScreeningToolsResourcePacket-
Revised-07312017.pdf 
– http://www.ilpqc.org/docs/toolkits/MNO-OB/5Ps-
Screening-Tool-and-Follow-Up-Questions.pdf 
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For the provider, an effective brief 
intervention consists of three tasks: 
1) provide feedback of personal 
responsibility (e.g., “As your doctor, 
I recommend you stop smoking 
cigarettes for your health and to 
improve your chances of getting 
pregnant, but it's your decision on 
what you want to do.”); 2) listen and 
understand a patient's motivation for 
using one or more substances (e.g., 
“I hear that you use pills to deal with 
the pain of your pregnancy losses.”); 
and 3) explore other options to 
address patient's motivation for 
substance use (e.g., “Are there other 
ways you deal with stress in a more 
healthy way?”).33 
 
The brief intervention can be 
followed with an oral or written 
‘‘contract’’ in which the patient states what he or she plans on doing to reach readiness, 
abstinence, or interim goals toward eliminating substance use, and the provider arranges for 
follow-up visits. This way, the patient remains responsible for his or her treatment and outcome, 
not the provider.
34
 
C. Referral to Treatment  
According to the CDC, the prevalence of OUD among primary care patients with chronic pain on 
opioid therapy is 3% to 26%. If clinicians suspect opioid use disorder based on patient concerns 
or behaviors or on findings in prescription drug monitoring program data, they should discuss 
their concerns with their patients and provide an opportunity for these patients to disclose related 
concerns or problems. Clinicians can assess for the presence of opioid use disorder using the 
DSM-5 criteria. Alternatively, clinicians can administer screening questions listed above and/or 
validated screening tools. If the score is moderate to high, they can arrange for a substance use 
disorder treatment specialist to assess for the presence of opioid use disorder.
35
 
 
The CDC Guideline suggests that clinicians should refer patients to treatment options for OUD. 
Specifically, the recommendations indicate that clinicians offer or arrange evidence-based 
treatment (usually MAT with buprenorphine or methadone in combination with behavioral 
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 “CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016,” 33. 
The CDC Recommendations for  
Assessing Risk and Addressing Harms of Opioid Use 
 
1. Naloxone: Incorporate strategies to mitigate risk, including 
considering offering naloxone when factors that increase risk for 
opioid overdose, such as history of overdose and/or SUD, higher 
opioid dosages (=50 MME/day), or concurrent benzodiazepine use, 
are present. 
2. PDMP: Review state prescription drug monitoring program data 
when starting opioid therapy for chronic pain and periodically during 
opioid therapy for chronic pain, ranging from every prescription to 
every 3 months. 
3. Urine Testing: For chronic pain, use urine drug testing before 
starting opioid therapy and consider urine drug testing at least 
annually to assess for prescribed medications as well as other 
controlled prescription drugs and illicit drugs. 
4. Benzodiazepines: Avoid prescribing opioid pain medication and 
benzodiazepines concurrently whenever possible. 
5. MAT: Clinicians should offer or arrange evidence-based treatment 
(usually MAT with buprenorphine or methadone in combination with 
behavioral therapies) for patients with OUD. 
11 
therapies) for patients with OUD.
36
 In addition to referring to MAT, the recommendation 
suggests that clinicians refer patients to behavioral health therapy. 
 
 
 
D. Medication Assisted Treatment (MAT) 
Recommendation 12 in the CDC Guideline, described above, suggests that clinicians refer 
patients with OUD to evidence-based treatment, usually MAT with buprenorphine or methadone 
in combination with behavioral therapies.
37
 MAT is a multimodal and comprehensive treatment 
approach that should include a psychosocial component, such as cognitive behavioral therapy, 
motivational enhancement therapy, or peer-delivered recovery support service.
38
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38
 G. E. Moran, C. M. Snyder, R. F. Noftsinger, and J. D. Noda, “Implementing Medication-Assisted Treatment for 
Opioid Use Disorder in Rural Primary Care: Environment Scan (Volume 1),” Agency for Healthcare Research and 
Quality, October 2017, 5, 
https://integrationacademy.ahrq.gov/sites/default/files/mat_for_oud_environmental_scan_volume_1_1.pdf. 
Provider Training and Patient Referral Resources  
 
 
Massachusetts  
 Massachusetts Department of Public Health, Bureau of Substance Abuse Services (MDPH, BSAS) 
State Technical Assistance Treatment Expansion (STATE) OBAT Program: Provides free training 
and technical assistance on addiction treatment to providers in Massachusetts.  
 Substance Use Disorder Services Helpline: A statewide, public resource for finding substance use 
treatment and recovery services, funded by the Massachusetts Department of Public Health.  
 
Federal – Substance Abuse and Mental Health Services Administration (SAMHSA) 
 Buprenorphine physician locator: Provides a list of physician names, addresses and phone numbers 
authorized to treat OUD with buprenorphine by state. 
 Opioid Treatment Program Directory: Provides a list of opioid treatment program names, addresses, 
and phone numbers, by state.  
 Provider Clinical Support System for Opioid Therapies: Offers extensive experience in the treatment 
of substance use disorders and specifically of opioid use disorder, as well as expertise on the interface of 
pain and opioid misuse.  
 Provider’s Clinical Support System for MAT: Offers expert physician mentors to answer questions 
about assessment for and treatment of substance use disorders. 
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MAT is used to prevent the euphoric 
effects of opioids, lessen cravings for 
opioids, and decrease withdrawal 
symptoms by acting as opioid agonists, 
partial agonists, or antagonists.
39
 There 
are three medications that are currently 
approved by the Food and Drug 
Administration for opioid use disorder: 
methadone, buprenorphine, and 
naltrexone.
40
 Each of these 
medications has its uses and 
restrictions for use. Methadone is an 
opioid agonist used to minimize 
withdrawal symptoms and can only be 
dispensed in opioid treatment 
programs certified by the Substance 
Abuse and Mental Health Services 
Administration (SAMHSA) and 
registered with the U.S. Drug 
Enforcement Agency (DEA).
41
 
Methadone has also been used to 
provide relief for chronic or acute pain 
with a slow release effect used for 
some pain management cases.  Like 
other common pain medications, it can 
lead to addiction and/or overdose if not 
taken as prescribed. However, over the 
past few decades, methadone has been 
used to help treat opioid use disorder 
mainly because it does not produce 
euphoric effects and must be dispensed 
in a controlled environment.  
 
Buprenorphine is a partial opioid 
agonist and can be used for withdrawal 
and treatment; however, the use of buprenorphine for “maintenance treatment involves some risk 
of misuse or overdose.”42 Unlike buprenorphine and methadone, naltrexone is an opioid 
antagonist that blocks opioid receptors to prevent any of the effects of opioids if they are used. 
Therefore, it is recommended for relapse prevention rather than for management of withdrawal 
                                                          
39
 Moran et al. “Implementing Medication-Assisted Treatment for Opioid Use Disorder in Rural Primary Care: 
Environment Scan (Volume 1),” 5. 
40
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41
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42
 Moran et al. 4. 
MA Bureau of Substance Abuse Services and Department of 
Mental Health Guidelines for Administering MAT (2019) 
 Any physician or other authorized hospital staff in Department of 
Mental Health (DMH)-licensed inpatient facilities can administer or 
dispense methadone and buprenorphine without additional state or 
federal oversight or approval, provided the methadone or 
buprenorphine is administered or dispensed incident to the patient’s 
medical treatment for a condition other than substance use disorder.  
This includes MAT induction for a patient with a secondary diagnosis 
of substance use disorder on either methadone or buprenorphine.  
o DEA regulations (21 CFR 1306.07) authorize physicians or 
other authorized hospital staff to administer or dispense 
buprenorphine or methadone in the hospital, which includes 
psychiatric hospitals, in order to maintain or detox a patient 
“as an incidental adjunct to medical or surgical treatment of 
conditions other than addiction.” In effect, this allows a 
physician or other authorized hospital provider to administer 
or dispense MAT to patients at the hospital, without time 
limitation, where SUD is a secondary diagnosis.   
 Any physician in DMH-licensed inpatient facilities can administer 
methadone or buprenorphine without additional state or federal 
oversight or approval pursuant to the DEA’s “three day rule.”   
o DEA regulations (21 CFR 1306.07) authorize physicians to 
administer buprenorphine or methadone to a patient “for the 
purpose of relieving acute withdrawal symptoms when 
necessary while arrangements are being made for referral to 
treatment.” This treatment is limited to 72 hours, where not 
more than one day’s medication is administered to the person 
at a time. The 72-hour period cannot be renewed. In effect, 
this allows a physician to administer MAT to patients where 
SUD is the primary diagnosis solely for the purpose of 
managing their withdrawal.   
For additional information: 
– Guidelines for Medication for Addiction Treatment for Opioid Use 
Disorder within the Emergency Department 
– Code of Federal Regulations 
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symptoms. Naltrexone does not carry a risk for abuse or overdose like buprenorphine or 
methadone, so health care providers have no restrictions prescribing it.
43
 
 
Physicians not already certified to provide buprenorphine in an office-based setting can undergo 
training to receive a waiver from SAMHSA that allows them to prescribe buprenorphine to treat 
patients with opioid use disorder. The CDC suggests that physicians prescribing opioids in 
communities without sufficient treatment capacity for opioid use disorder should strongly 
consider obtaining this waiver. Clinicians do not need a waiver to offer naltrexone for opioid use 
disorder as part of their practice.
44
 
 
IV. What are the Unique Considerations by Select Populations? 
As with delivery of any services, there are unique considerations that providers can take into 
account for select populations. Below are considerations for individuals living in rural areas, 
women who are pregnant or postpartum, and individuals with mental health comorbidities. 
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Prescribing Naloxone 
 
In order to reduce the risk of overdose deaths, clinicians should strongly consider prescribing or co-prescribing 
naloxone, and providing education about its use for the following patients who are at risk of opioid overdose: 
 
Patients prescribed opioids who: 
 Are receiving opioids at a dosage of 50 MME per day or greater. 
 Have respiratory conditions such as chronic obstructive pulmonary disease (COPD) or obstructive sleep 
apnea (regardless of opioid dose). 
 Have been prescribed benzodiazepines (regardless of opioid dose). 
 Have a non-opioid substance use disorder, report excessive alcohol use, or have a mental health disorder 
(regardless of opioid dose). 
Patients at high risk for experiencing or responding to an opioid overdose, including individuals: 
 Using heroin, illicit synthetic opioids, or misusing prescription opioids. 
 Using other illicit drugs such as stimulants, including methamphetamine and cocaine, which could 
potentially be contaminated with illicit synthetic opioids like fentanyl. 
 Receiving treatment for opioid use disorder, including MAT with methadone, buprenorphine, or naltrexone. 
 With a history of opioid misuse and recently released from incarceration or other controlled settings where 
tolerance to opioids has been lost. 
 
Additional information available from source where above content was directly extracted from: 
Naloxone: The Opioid Reversal Drug that Saves Lives  
https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf 
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A. Rural 
The CDC has estimated that people in rural counties are approximately twice as likely as those in 
urban areas to overdose on prescription painkillers. Several theories are hypothesized as to 
explain the differences between rural and urban populations, including: increased availability of 
opioids in states with large rural populations because of high prescription rates; large kinship 
networks unique to rural areas that may contribute to the spread of prescription opioids, as 
friends and family with prescriptions are often a main source of access to these drugs; and 
individuals living in rural areas being more likely to suffer injuries in labor occupations that lead 
to higher rates of chronic pain and prescription opioid abuse.
45
 
 
Additionally, individuals with OUD in rural counties often lack access to MAT. For example, 
although primary care physicians are important providers of health care in rural areas, one study 
found that only 3% of these physicians had obtained a waiver to prescribe buprenorphine.
46
 Due 
to this lack of waivered physicians, approximately 21 million people were living in rural counties 
with no local access to physicians authorized to provide buprenorphine treatment.
47
 The majority 
of waived providers are in urban areas.  
 
 
“Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis,” chart information 
from J. A. Barocas et al. American Journal of Public Health, November 7, 2018. 
 
Another potential driving force is that rural residents may experience health inequities shaped by 
social determinants of health. Lower levels of education, living in poverty, and possible lower 
health literacy all impact the ability to manage chronic pain, adhere to instructions for 
medication, and/or communicate with providers.
48
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B. Pregnancy and Post-partum  
Providers should exercise additional caution when it comes to women who are pregnant or are 
postpartum. The CDC recommendations note that opioids used in pregnancy can lead to risks to 
both mother and fetus. Studies have shown “opioid use during pregnancy leads to neonatal 
opioid withdrawal syndrome.”49 Additionally, there is 
moderate evidence describing the risk of developing 
chronic pain in the postpartum period due to mode of 
delivery, though data regarding chronic pain 
conditions that develop during pregnancy are 
minimal.
50
  
 
For pregnant women already receiving opioids, the 
CDC recommends that clinicians should “access 
appropriate expertise if considering tapering opioids 
because of possible risk to the pregnant patient and to 
the fetus if the patient goes into withdrawal.”51 The 
CDC recommendations also note that MAT, such as 
buprenorphine or methadone, has been associated 
with improved maternal outcomes and should be 
offered. Recent research has suggested that methadone exposure in utero has a higher risk for 
neonatal abstinence syndrome compared with buprenorphine exposure.
 52
 Another study 
suggested that Suboxone (MAT that combines buprenorphine and naloxone) may be a better 
option for women with a history of light to moderate opiate abuse, while methadone may be 
more effective for women who are heavy, chronic users.
53
 Additionally, the CDC guidelines note 
that for women who are taking opioids for pain or are receiving MAT, clinicians should ensure 
that pregnant women can deliver at a facility prepared to “monitor, evaluate for, and treat 
neonatal opioid withdrawal syndrome.”54  
 
The CDC recommendations note that before starting opioid therapy for chronic pain for women 
of reproductive age, “clinicians should discuss family planning and how long-term opioid use 
might affect any future pregnancy.”55 For example, clinicians can use the One Key Question® 
approach
56
 and ask women of reproductive age the question “Would you like to become pregnant 
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the Literature,” International Journal of Women’s Health, no. 10 (2018): 158.  
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 Lemon LS, Caritis SN, Venkataramanan R, Platt RW, Bodnar LM. Methadone versus buprenorphine for opioid 
use dependence and risk of neonatal abstinence syndrome [published online November 6, 2017]. Epidemiology. doi: 
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53
 Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: A review of evidence in both 
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 Baldwin, M. K., Overcarsh, P., Patel, A., Zimmerman, L., & Edelman, A. (2018). Pregnancy intention screening 
tools: a randomized trial to assess perceived helpfulness with communication about reproductive 
goals. Contraception and reproductive medicine, 3, 21. doi:10.1186/s40834-018-0074-9 
Title X  
 
Founded in 1970 
 
The only federal 
program dedicated to 
providing family 
planning and related 
preventive services. 
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in the next year?” to facilitate a client-centered conversation with women. Providers can also 
partner with family planning providers in their community, such as Title X family planning 
service providers who have expertise in providing client-centered counseling and offer a wide 
range of contraceptive options, if the woman decides to pursue opioid therapy.  
C. Mental Illness  
Viewing OUD as a stand-alone disease without consideration of other substance use or comorbid 
psychiatric pathology provides only a limited perspective. OUD evaluation and treatment should 
also specifically focus on psychiatric symptomatology and comorbidity. Individuals with mental 
health comorbidities and individuals with histories of substance use disorders might be at higher 
risk than other patients for opioid use disorder.
57
 
 
It is estimated that among the 38.6 million Americans with mental health disorders, 18.7% (7.2 
million of 38.6 million) use prescription opioids.
58
Adults with mental health conditions receive 
51.4% (60 million of 115 million prescriptions) of the total opioid prescriptions distributed in the 
U.S. each year.
59
 Compared with adults without mental health disorders, studies indicate that 
adults with mental health disorders were significantly more likely to use opioids. 
  
In addition, studies suggest that adults with mental health disorders (i.e., mood and anxiety 
disorders) are more likely to be prescribed opioids and remain taking them long term.
60
 For 
example, adults with mood disorders are nearly twice as likely to use opioids long term for 
pain.
61
 In fact, pain is very common among adults with mental health disorders,
62 
and the 
relationship between mental illness and opioid use is complex. However, some suggest that 
mental illness may be a moderator in the relationship between pain and opioid use.
63
 
 
Conclusion 
While there are significant efforts underway to combat the opioid crisis, there remains a need for 
greater emphasis on overdose prevention and treatment, and on coordination of efforts and best 
practices. It is important to amplify implementation of preventive measures, physician education, 
and addressing why patients are using opioids in the first place. Dissemination of MAT and 
opioid overdose medication naloxone is another critical component in addressing OUD. Lastly, 
there are unique considerations for prescribing opioids by different areas of medical specialty. 
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The focus of OUD must be comprehensive and should not be considered a stand-alone disease 
without consideration of other substance use or comorbid psychiatric pathology. 
 
In summary, the goal of this Advisory is to supplement and support practitioners in the review 
and development of judicious and balanced opioid prescribing practices. It is not intended to be 
an algorithm in the treatment of acute or chronic pain or to replace good clinical judgment, a 
longitudinal professional relationship with the patient, frequent monitoring or discontinuation of 
prescribing when unsafe. More importantly, physicians should treat patients' pain appropriately, 
without fear of discipline if done with careful prescribing. 
 
 
MASSACHUSETTS RESOURCE WEBSITES 
1. Opioid Law Updates: https://www.mass.gov/news/update-for-prescribers-new-law-
regarding-opioids 
2. DPH Pamphlet for CII and CIII  Narcotic Dispensing: 
https://mass.gov/files/documents/2016/09/rf/opiod-fact-sheet_0.pdf 
3. Naloxone Dispensing via Standing Order DCP/Pharmacy Jointly: 
https://mass.gov/files/documents/2018/12/13/naloxone-dispensing-via-standing-order.pdf 
4. Naloxone Exchange (DCP): 
https://www.mass.gov/files/documents/2019/02/26/naloxone-exchange-chapter-208-
final.pdf 
5. Voluntary Non-Opioid Directive Form: 
https://www.mass.gov/files/documents/2017/01/xd/non-opioid-directive_0.pdf  
6. Sale of hypodermic Syringes and Needles Pharmacy:  
https://www.mass.gov/files/documents/2019/03/01/sale-syringe-hypodermic.pdf  
7. Pharmacist Administration of MH/SUD Medications. DCP/Pharmacy issued jointly: 
https://www.mass.gov/files/documents/2019/02/12/circular-dcp-19-2-105.pdf  
8. Partial Fill DCP/Pharmacy issued jointly: 
https://www.mass.gov/files/documents/2018/08/23/dcp-16-12-665.pdf    
9. DCP/Pharmacy updated jointly: https://www.mass.gov/files/documents/2018/11/06/dcp-
partial-fill.pdf  
10. Drug Stewardship Program Instructions: 
https://www.mass.gov/files/documents/2017/03/zu/dhcq-666.pdf  
11. PMP Utilization for Benzodiazepines: 
https://www.mass.gov/files/documents/2018/11/01/pmp-benzo-check-notice%20208-of-
2018_0.pdf 
     
12. Virtual Manufacture or Distributor MCSR Application: 
https://www.mass.gov/files/documents/2018/11/05/app-vitrtualmanufdistrib-mcsr.pdf  
13. Permitted Prescription Changes: https://www.mass.gov/policy-advisory/2018-01-
permitted-prescription-changes  
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